Home » Healthcare » Pharmaceuticals » Hereditary Angioedema Market

Hereditary Angioedema Market By Drug Class (C1 Esterase Inhibitors, Kallikrien Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Product Drugs (Phase Iii Drug, Phase Ii Drug (Qualitative Information) ) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Summary
Table Of Content

Market Insights

Hereditary angioedema is a disorder that results in frequent attacks of pain and inflammation accompanied by swelling of the legs, intestinal tract, arms, face, and airway tract. There are three types of hereditary angioedema, types I, II, and III, which are distinguished by the underlying causes and the levels of a blood protein called C1 inhibitors. The phenotypic expression of hereditary angioedema varies widely, even among family members; the frequency and severity of attacks are unpredictable, giving the impression that similar symptoms arise in all types. Type III was initially thought to be prevalent only in women, but incidences have occurred in males in the same affected families.

For the purpose of this study, the global hereditary angioedema market is studied in terms of drug classes, pipeline drugs, and geography. The drug classes studied in the report include C1 esterase inhibitors (Berinert, Haegarda, Cinryze, and Ruconest), kallikrein inhibitors (Kalbitor), selective bradykinin B2 receptor antagonists (Firazyr), others. DX-2930, a phase III drug, and BCX-7353, a phase II drug, are currently in the pipeline for this market. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The geographic segmentation of the global hereditary angioedema market is performed for the regions of North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global hereditary angioedema market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global hereditary angioedema market. The key players profiled in this report are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

Based on drug class, the global hereditary angioedema market is categorized into:

C1 Esterase Inhibitors
Berinert
Haegarda
Cinryze
Ruconest
Kallikrein Inhibitor
Kalbitor
Selective Bradykinin B2 Receptor Antagonist
Firazyr
Others

The hereditary angioedema market is driven by factors such as increasing expenditure in pharmaceutical and biotechnology R&D focusing on rare genetic diseases, rising public awareness, and alliances between pharmaceutical giants and research institutes. In addition, the increasing number of diagnostic centers and growing physician awareness regarding disease etiology will propel the market penetration of hereditary angioedema drugs. In 2016, the C1 esterase inhibitors segment held the largest market share, chiefly due to factors such as the recent FDA approval of Berinert and Haegarda.

Technological advancement in the drug delivery system, e.g., Haegarda, is the only medication available as a subcutaneous treatment option for hereditary angioedema. Kallikrein inhibitors will be the fastest-growing segment throughout the forecast period of 2017–2025. Factors contributing to the growth of this segment include increasing incidences in patients with angioedema and anaphylactic shock and a promising product pipeline consisting of selective kallikrein inhibitors and plasma kallikrein inhibitors, which result in immediate relief due to their faster onset of action. The major players in the hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd.

For the purpose of this study, the global hereditary angioedema market is categorized into the following regional and country-specific markets:

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

In the base year 2016, North America was observed to be the largest market for hereditary angioedema. According to the US Hereditary Angioedema Association, in 2016, about 3,904 people suffered from hereditary angioedema. The dominance of North America is mainly attributed to the presence of key drivers such as the rising prevalence of hereditary angioedema, the presence of pharmaceutical giants such as Bio Cryst Pharmaceuticals, Inc. and CSL Behring, and the existence of developed research and healthcare institutions.

The market growth in Europe is mainly attributed to the rising prevalence of rare genetic diseases, the increasing demand for novel drugs for the treatment of hereditary angioedema, and an affordable reimbursement scenario for the treatment of rare genetic diseases. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are increasing disposable income and a supportive regulatory environment for hereditary angioedema products. Moreover, factors such as developing health infrastructure and expansion by pharmaceutical giants in the untapped market of remote areas with unmet medical needs are going to fuel the rapid growth of the hereditary angioedema market in Latin America, the Middle East, and Africa in the near future.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Hereditary Angioedema Market Portraiture
2.1.1. Global Hereditary Angioedema Market, by Drug Class, 2016
2.1.2. Global Hereditary Angioedema Market, by Geography, 2016

Chapter 3. Hereditary Angioedema: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Competitive Landscape
3.6.1. Competitive Landscape, by Key Players, 2016

Chapter 4. Global Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Hereditary Angioedema Market, by Drug Class
4.3. C1 Esterase Inhibitors
4.3.1. Berinert
4.3.2. Haegarda
4.3.3. Cinryze
4.3.4. Ruconest
4.4. Kallikrien Inhibitor
4.4.1. Kalbitor
4.5. Selective Bradykinin B2 Receptor Antagonist
4.5.1. Firazyr
4.6. Others

Chapter 5. Global Hereditary Angioedema Market, by Product Drugs, 2015 – 2025 (US$ Mn)
5.1. Overview
5.2. Phase III Drug
5.2.1. DX-2930
5.3. Phase II Drug (Qualitative Information)
5.3.1. BCX-7353

Chapter 6. Global Hereditary Angioedema Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Hereditary Angioedema Market Analysis, 2015 – 2025
6.2.1. North America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.2.2. North America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.2.2.1. U.S.
6.2.2.2. Canada
6.3. Europe Hereditary Angioedema Market Analysis, 2015 – 2025
6.3.1. Europe Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.3.2. Europe Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.3.2.1. U.K.
6.3.2.2. Germany
6.3.2.3. France
6.3.2.4. Rest of Europe
6.4. Asia Pacific Hereditary Angioedema Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.4.2.1. Japan
6.4.2.2. China
6.4.2.3. India
6.4.2.4. Rest of APAC
6.5. Latin America Hereditary Angioedema Market Analysis, 2015 – 2025
6.5.1. Latin America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
6.5.2.1. Brazil
6.5.2.2. Mexico
6.5.2.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Hereditary Angioedema Market Analysis, 2015 – 2025
6.6.1. MEA Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
6.6.2. MEA Hereditary Angioedema Market, by Region, 2015 – 2025 (US$ Mn)
6.6.2.1. GCC
6.6.2.2. Rest of MEA

Chapter 7. Company Profiles
7.1. BioCryst Pharmaceuticals, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Cipla, Inc.
7.3. CSL Behring Ltd.
7.4. Ionis Pharmaceuticals, Inc.
7.5. iBio, Inc.
7.6. Merck & Co., Inc.
7.7. Pharming Group NV
7.8. Sanofi N.V.
7.9. Shire plc.
7.10. Teva Pharmaceutical Industries, Ltd.
7.11. Other Notable Players

List of Figures

FIG. 1 Hereditary Angioedema: Market Segmentation
FIG. 2 Global Hereditary Angioedema Market Share, by Drug Class, 2016 (Value %)
FIG. 3 Global Hereditary Angioedema Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition, by Geography
FIG. 5 Market Competition Landscape, by Key Players, 2016
FIG. 6 Global C1 Esterase Inhibitors Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Berinert Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Haegarda Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Cinryze Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Ruconest Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Kalbitor Market, 2015 – 2025 (US$ Mn)
FIG. 12 Global Firazyr Market, 2015 – 2025 (US$ Mn)
FIG. 13 Global Other Drug Class for Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.S. Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 15 Canada Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 16 U.K. Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 17 Germany Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 18 France Hereditary Angioedema Market, 2015-2025 (US$ Mn)
FIG. 19 Rest of Europe Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 20 Japan Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 21 China Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 22 India Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 23 Rest of Asia Pacific Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 24 Brazil Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 25 Mexico Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 26 Rest of Latin America Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 27 GCC Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)
FIG. 28 Rest of Middle East and Africa Hereditary Angioedema Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 2 Global Hereditary Angioedema Market, by Pipeline Drugs, 2015 – 2025 (US$ Mn)
TABLE 3 Global Hereditary Angioedema Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 5 North America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 6 Europe Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Asia Pacific Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 10 Latin America Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Hereditary Angioedema Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 12 Middle East and Africa Hereditary Angioedema Market, by Drug Class, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Hereditary Angioedema Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 14 BioCryst Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 15 Cipla, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 16 CSL Behring Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 17 Ionis Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 18 iBio, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 19 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 Pharming Group NV: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Sanofi N.V.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Shire plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Teva Pharmaceutical Industries, Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Hereditary Angioedema Market?

The market for Hereditary Angioedema Market is expected to reach US$ 3,689.4 Mn By 2025.

What is the Hereditary Angioedema Market CAGR?

The Hereditary Angioedema Market is expected to see significant CAGR growth over the coming years, at 8.19%.

What is the Forecast period considered for Hereditary Angioedema Market?

The report is forecasted from 2017-2025.

What is the base year considered for Hereditary Angioedema Market?

The base year of this report is 2016.

Who are the major players in this market?

Cipla, Inc., CSL Behring Ltd., Ionis Pharmaceuticals, Inc., iBio, Inc., Merck & Co., Inc., Pharming Group NV, Sanofi N.V., Shire plc, and Teva Pharmaceutical Industries Ltd. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Enterprise

$5699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –